$JAZZ

AI 分析

生成于 May 11, 2026

AI Score
68/ 100
Hold$JAZZ

Jazz Pharmaceuticals

$JAZZNASDAQHealthcareLarge-Cap

Jazz develops and commercializes medicines for neuroscience and oncology including Xywav for narcolepsy.

Market Cap
$8.0B
Revenue (TTM)
$3.8B
+5.0%
Net Income (TTM)
$0.5B
+8.0%
EPS (TTM)
$7.50
P/E Ratio
16.0
Dividend Yield
0.0%
52-Week Range
$100-$175
Beta
0.62
Dimension Scores
Fundamental
70
Technical
62
Sentiment
66
Risk / Reward
72
Momentum
60
FundTechSentRiskMome
Financial Health
Profitability
75moderate
Growth
63moderate
Liquidity
80strong
Solvency
72strong
Efficiency
68strong

Valuation, technical analysis, investment thesis, risk assessment and more for $JAZZ

Free · No credit card required

免责声明: AI 生成的分析仅供教育参考,不构成投资建议。请始终咨询合格的理财顾问。

探索更多

用 AI 分析任意股票

获取涵盖基本面、技术面、情绪面、风险评估和投资论点的结构化研究报告——约 60 秒完成。